Jantec Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
About Jantec Pharma
Jantec Pharma Private Limited (JPPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 June 2010 and has a history of 14 years and eight months. Its registered office is in Delhi, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ashutosh Pataudi and Satpal serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232DL2010PTC203856
- Company No.
203856
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jun 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Jantec Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashutosh Pataudi  | Director | 20-Nov-2019 | Current |
| Satpal | Director | 21-Jan-2019 | Current |
Financial Performance of Jantec Pharma.
Jantec Pharma Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Jantec Pharma?
In 2017, Jantec Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sunwealth Real Estates LimitedAshutosh Pataudi is a mutual person
- Sunwealth International Limited
Ashutosh Pataudi is a mutual person
- S P Jindal Real Estates Limited
Ashutosh Pataudi is a mutual person
- Blue Bull Films Private Limited
Ashutosh Pataudi is a mutual person
- S P Jindal Technologies Limited
Ashutosh Pataudi is a mutual person
- S P Jindal Ventures India Limited
Ashutosh Pataudi is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Jantec Pharma?
Unlock and access historical data on people associated with Jantec Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jantec Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jantec Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
